Compare CLPS & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLPS | BTAI |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.0M | 35.6M |
| IPO Year | 2017 | 2018 |
| Metric | CLPS | BTAI |
|---|---|---|
| Price | $0.88 | $1.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 10.5K | ★ 882.4K |
| Earning Date | 03-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 14.86% | N/A |
| EPS Growth | N/A | ★ 75.63 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $141.28 |
| Revenue Next Year | N/A | $1,921.56 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $1.08 |
| 52 Week High | $1.88 | $8.08 |
| Indicator | CLPS | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 28.91 | 32.20 |
| Support Level | $0.83 | N/A |
| Resistance Level | $0.96 | $1.77 |
| Average True Range (ATR) | 0.04 | 0.12 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 6.72 | 8.21 |
CLPS Inc. is an IT consulting and solutions provider serving international clients in the banking, wealth management, e-commerce, and automotive sectors. The company drives digital transformation using AI, cloud computing, and big data, offering IT consulting, customized solutions, virtual banking training, recruitment, professional training, and software services. It operates mainly in two segments: IT services, which generate the majority of its revenue, and academic education services. The company has a presence in Hong Kong, Singapore, Mainland China, India, Malaysia, and Japan, with the majority of its revenue coming from Mainland China.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.